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Abstract Over the last decade vancomycin-resistant en-
terococci (VRE) have emerged as nosocomial patho-
gens. The aim of this study was to determine the
prevalence of VRE in clinical samples from hospitalized
patients in the Canary Islands. From April to November
2000, 437 enterococci were isolated from patients hos-
pitalized at the four main health care centers in those
islands. Identiﬁcation to the species level was performed
with the GPS-TA (Vitek 1) or the Wider I system. A
PCR assay was used to determine the genotype of gly-
copeptide resistance (vanA, vanB, vanC1, and vanC2/C3
genes). Only three (0.7%) VRE were detected: one vanA
Enterococcus faecalis, and two vanC1 Enterococcus
gallinarum. To our knowledge, this is the ﬁrst VRE
study carried out in the Canary Islands hospitals, and
the results showed a low prevalence of VRE.
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Introduction
Vancomycin-resistant enterococci (VRE) have emerged
as a major cause of nosocomial infections [2, 13, 14, 21].
Since their initial isolation from patients in the United
Kingdom and France, VRE infections have been in-
creasingly detected throughout the world [23]. These
bacteria are often resistant to multiple antibiotics, thus
limiting the number of therapeutic options available to
the physician [9]. Among isolates from United States
hospitals, resistance to vancomycin rose from 0.3% in
1989 to 15.4% in 1997 [5, 14]. In contrast, the prevalence
of VRE in European hospitals is low, being 1.8% in
Spain [3, 22].
Vancomycin is a member of a class of antibiotics
referred to as glycopeptides. These antibiotics interfere
with peptidoglycan biosynthesis by binding to the ter-
minal D-alanyl-D-alanine residue of the peptidoglycan
precursor [23]. Seven glycopeptide resistance genotypes
have been described in enterococci [2, 12, 13]. Five of
these (vanA, vanB, vanD, vanE and vanG) are acquired
mechanisms and the other two (vanC1 and vanC2/C3)
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are intrinsic properties. The vanA and vanB resistance
genotypes are the most commonly found. The vanA gene
cluster encodes proteins that confer high-level resistance
to both vancomycin and teicoplanin [1]. The expression
of vanA genes is induced by either vancomycin or tei-
coplanin. The vanB genes confer resistance to various
concentrations of vancomycin but not teicoplanin [6,
13], and are induced only by vancomycin and not by
teicoplanin. The VanA phenotype is distributed world-
wide, and is by far the predominant type of vancomycin
resistance reported in Europe [20]. Although VanA is the
predominant type, VanB strains are fairly common in
the Unites States [2]. The vanC1 and vanC2/C3 genes are
speciﬁc to the motile VRE species Enterococcus galli-
narum and E. casseliﬂavus/E. ﬂavescens, respectively [4].
The other genotypes, vanD, vanE and vanG, have been
detected in only a few enterococcal strains [8, 12, 16, 19].
In this report, we provide data on the prevalence of
VRE in clinical samples from hospitalized patients in the
Canary Islands. These islands, which constitute an au-
tonomous region of Spain, are located in the Atlantic
ocean oﬀ the coast of North-West Africa, and have a
population of approximately 1,700,000. In our hospitals,
vancomycin is frequently prescribed due to the high
prevalence of methicillin-resistant Staphylococcus aureus
[18]. To our knowledge, this is the ﬁrst study on VRE
carried out in the Canary islands.
Materials and methods
Patients, bacterial isolates and reference strains
The four main hospitals in the Canary Islands are 500- to 900-bed
health care centers, two of which are located in the island of
Tenerife (Nuestra Sen˜ora de Candelaria University Hospital and
Canarian University Hospital) and the other two in the island of
Gran Canaria (Dr. Negrı´n Hospital and Insular Hospital). These
hospitals provide tertiary care for most of the population of the
islands. During a 9-month period (April–November 2000), we
studied 406 enterococcal clinical isolates collected from patients
hospitalized at the four hospitals. A single specimen was obtained
from each subject. The isolations, approximately 100 per hospital,
were carried out by the Microbiology Service of each hospital. The
isolates from clinical samples came from urine (173), wounds (118),
blood (46), catheter tips (29), respiratory tract (13), and other
clinical materials (27). A total of 31 colonizers, isolated from rectal
cultures in adults, were also included in the study. The following
reference strains were used: E. faecium BM4147 (vanA), E. faecalis
V583 (vanB), E. gallinarum BM4174 (vanC1), E. casseliﬂavus
ATCC 25788 (vanC2), and E. faecalis ATCC 29212 as a glyco-
peptide-susceptible control. S. aureus ATCC 29213 was used as a
negative control.
Phenotypic identiﬁcation and susceptibility testing
Bacterial isolates were processed by agar bile-esculin-vancomycin
(6 lg/ml) screening to detect enterococcal colonies and vancomycin
resistance. Isolates were identiﬁed to the species level with the GPS-
TA (Vitek 1) system (bioMe´rieux, Marcy l’Etoile, France) except
those from the Hospital Insular (Las Palmas de Gran Canaria),
which were identiﬁed with the Wider I System (Dade Microscan,
West Sacramento, Calif.). The minimal inhibitory concentrations
(MIC) of vancomycin and teicoplanin for the resistant isolates were
determined by broth microdilution according to National Com-
mittee for Clinical Microbiology Standards guidelines [15]; both
antibiotics were tested in the range 0.25–128 lg/ml. VRE were also
tested with the E-test method (AB Biodisk, Solna, Sweden) ac-
cording to the manufacturer’s speciﬁcations. Biochemical identiﬁ-
cation of enterococci was performed according to standard
laboratory criteria [7].
PCR ampliﬁcation
We used a previously described PCR protocol for the simultaneous
detection of the most common vancomycin-resistance genotypes
(vanA, vanB, vanC1 and vanC2/C3) and identiﬁcation of Entero-
coccus isolates at the genus level [17]. Strains were grown overnight
at 37C on blood sheep agar plates (bioMe´rieux, Marcy l’Etoile,
France). Three to ﬁve colonies of each sample were scraped from
the surface of the agar and resuspended in 1 ml of sterile distilled
water. The cell suspension was heated to 100C for 15 min and was
then centrifuged at 15,000 g for 10 min. The DNA-containing
supernatant was used as a template. An aliquot of 20 ll of the
supernatant was added to 80 ll of a PCR mixture consisting of 1·
reaction buﬀer [16 mM (NH4)2SO4, 67 mM Tris-HCl, pH 8.8],
0.2 mM of each deoxyribonucleotide triphosphate (Promega,
Madison, Wis.), 2.5 mM MgCl2, 50 pmol of each primer, and
1.2 U Taq DNA polymerase (Bioline, UK). For each sample, the
PCR reaction was performed with the vanA, vanB, vanC1, vanC2/
C3 and Ent pairs of primers (Roche, Mannheim, Germany) in a
single tube [4, 10, 17]. A negative control without DNA template
was included in the assay. DNA ampliﬁcation was carried out in a
GeneAmp PCR system 9700 thermocycler (PE Applied Biosystems,
Calif.) with the following thermal cycling proﬁle: an initial dena-
turation step at 94C for 2 min was followed by 25 cycles of am-
pliﬁcation (94C for 60 s, 55C for 60 s, and 72C for 60 s), and an
extension at 72C for 5 min. PCR products were resolved by
electrophoresis on a 1.5% agarose gel stained with ethidium bro-
mide. A 100-bp DNA ladder (Roche, Mannheim, Germany) was
run in each gel, and the VRE genotype was determined by the size
of the ampliﬁed product.
Results and discussion
A total of 437 enterococci isolates were obtained from
clinical samples in the four main hospitals of the Canary
Islands. Table 1 shows their phenotypic identiﬁcation.
E. faecium was the most abundant species (86.2%). The
two E. gallinarum isolates had been initially identiﬁed as
Table 1. Enterococcal isolates
and vancomycin resistance
genotypes
Species No. (%)
of isolates
No. of vancomycin-
resistant enterococci (VRE)
Resistance
genotype (%)
Enterococcus faecalis 377 (86.3) 1 vanA (0.2)
E. faecium 52 (11.9) 0 –
E. avium 4 (0.9) 0 –
E. durans 2 (0.5) 0 –
E. gallinarum 2 (0.5) 2 vanC1 (0.5)
Total 437 (100) 3 van (0.7)
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E. faecium and Enterococcus sp. with the automated
system. Further biochemical and motility tests identiﬁed
them as E. gallinarum. Three VRE (0.7%) were detected:
one E. faecalis (UIE-478, isolated from blood of a can-
cer patient who had had vancomycin treatment) and the
two E. gallinarum (UIE-298 and UIE-470, isolated from
a new-born ear infection and a post-surgery abscess,
respectively). The automated system detected high-level
resistant isolates (VanA phenotype), but not low-level
resistant isolates (VanC phenotype). Using the agar di-
lution method, E. faecalis UIE-478 showed high-level
resistance to vancomycin (MIC >128 lg/ml) and to
teicoplanin (MIC >128 lg/ml), whereas E. gallinarum
UIE-470 and E. gallinarum UIE-298 showed low-level
vancomycin resistance (MIC =8 lg/ml) and teicoplanin
(MIC =1 lg/ml) susceptibility. By the E-test method,
E. faecalis UIE-478 had MICs of >256 lg/ml for
vancomycin and 128 lg/ml for teicoplanin; E. gallina-
rum UIE-470 had MICs of 8 lg/ml for vancomycin and
0.38 lg/ml for teicoplanin; and E. gallinarum UIE-298
had MICs of 4 lg/ml for vancomycin and 0.25 lg/ml for
teicoplanin. The VanA isolate, E. faecalis UIE-478, was
sensitive to penicillin-G, high concentrations of gen-
tamicin, and high levels of streptomycin, and therefore
did not represent a problem during treatment.
The results of the PCR assay with the 437 entero-
coccal isolates were in accordance with the phenotypic
characterization. Three VRE were detected (Table 1):
one vanA isolate, E. faecalis UIE-478, and two vanC1
isolates, E. gallinarum UIE-298 and UIE-470. The PCR
results obtained with reference strains E. faecium
BM4147 (vanA) and E. gallinarum BM4174 (vanC1)
were as expected (not shown). The rest of the clinical
isolates were all negative for the vanA, vanB, vanC1 and
vanC2/C3 genes (results not shown). The vanB gene was
not detected in any of the isolates.
In conclusion, this is the ﬁrst study of VRE isolated
from clinical samples from hospitalized patients in the
Canary Islands, and the results show a low prevalence
(0.7%) of VRE (0.2% for vanA gene and 0.5% for
vanC1 gene). This prevalence was lower than that re-
ported in other European countries and in the United
States [2, 11, 14, 22, 23]. Results of a recent VRE study
in Europe have shown that the United Kingdom has the
highest prevalence (2.9%), while other European coun-
tries have prevalence rates of 1% or lower. In Spain, a
multicenter study that did not include the Canary Islands
showed that the rate of resistance to glycopeptides was
1.8% [3]. E. gallinarum and E. casseliﬂavus isolates are
not always taken into account because their resistance to
glycopeptides is intrinsic and their pathogenesis is very
low. In our study, if we take out the two vanC1
E. gallinarum, the prevalence of VRE would be 0.2%,
which is even lower than previously reported levels [22].
Acknowledgements We thank Dr. Nadia Liassine, Central Labo-
ratory of Bacteriology, University Hospital, Geneva, for providing
reference strains. This work was supported by grants 1999/074 and
2001/020 from the Consejerı´a de Educacio´n, Cultura y Deportes,
Canary Island Autonomous Government, and FUNCIS PI 40/00,
Canary Island Autonomous Government to F.C.M., S.M.A. and
M.M. Work by S.M.A. was supported by FIS contract 99/3060
(Fondo de Investigacio´n Sanitaria, Spain).
References
1. Arthur M, Reynolds P, Courvalin P (1996) Glycopeptide
resistance in enterococci. Trends Microbiol 4:401–407
2. Cetinkaya Y, Falk P, Mayhall CG (2000) Vancomycin-resis-
tant enterococci. Clin Microbiol Rev 13:686–707
3. Cisterna R, Ibarra K, Morla A, Basaras M, Cisterna C,
Herreras A, Borja J, Grupo Espan˜ol de Estudio y Vigilancia de
Resistencias (1999) Estudio multice´ntrico de resistencias en
enterococos. Papel de la teicoplanina. Rev Esp Quimioter
12:237–243
4. Dutka-Malen S, Evers S, Courvalin P (1995) Detection of
glycopeptide resistance genotypes and identiﬁcation to the
species level of clinically relevant enterococci by PCR. J Clin
Microbiol 33:24–27
5. Endtz HP, van den Braak N, Verbrugh HA, van Belkum A
(1999) Vancomycin resistance: status quo and quo vadis. Eur
J Clin Microbiol Infect Dis 18:683–690
6. Evers S, Courvalin P (1996) Regulation of VanB-type vanco-
mycin resistance gene expression by the VanSB-VanRB two-
component regulatory system in Enterococcus faecalis V583.
J Bacteriol 178:1302–1309
7. Fackland RR, Sham DF, Teixeira LM (1999) Enterococcus. In:
Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH
(eds) Manual of clinical microbiology, 7th edn. American
Society for Microbiology, Washington, D.C., pp 297–305
8. Fines M, Perichon B, Reynolds P, Sahm DF, Courvalin P
(1999) VanE, a new type of acquired glycopeptide resistance in
Enterococcus faecalis BM4405. Antimicrob Agents Chemother
43:2161–2164
9. Gold HS (2001) Vancomycin-resistant enterococci: mechanism
and clinical observations. Clin Infect Dis 33:210–219
10. Ke D, Picard FJ, Martineau F, Me´nard C, Roy PH, Ouellette
M, Bergeron MG (1999) Development of a PCR assay for
rapid detection of enterococci. J Clin Microbiol 37:3497–3503
11. Low DE, Keller N, Barth A, Jones RN (2001) Clinical prev-
alence, antimicrobial susceptibility, and geographic resistance
patterns of enterococci: results from the SENTRY antimicro-
bial surveillance program, 1977–1999. Clin Infect Dis 15 [Sup-
pl 2]: S133–145
12. McKessar SJ, Berry AM, Bell JM, Turnidge JD, Paton JC
(2000) Genetic characterization of vanG, a novel vancomycin
resistance locus of Enterococcus faecalis. Antimicrob Agents
Chemother 44:3224–3228
13. Me´ndez-Alvarez S, Pe´rez-Herna´ndez X, Claverie-Martı´n F
(2000) Glycopeptide resistance in enterococci. Int Microbiol
3:71–80
14. Murray BE (2000) Vancomycin-resistant enterococcal infec-
tions. N Engl J Med 342:710–721
15. National Committee for Clinical Microbiology Standards
(1997) Performance standards for antimicrobial susceptibility
tests. Approved standard M2-A6. National Committee for
Clinical Laboratory Standards, Villanova, Pa.
16. Ostrowsky BE, Clark NC, Thauvin-Eliopoulus C, Venkatar-
aman L, Samore MH, Tenover FC, Eliopoulus GM, Moel-
lering RC Jr, Gold HS (1999) A cluster of VanD vancomycin-
resistant Enterococcus faecium: molecular characterization and
clinical epidemiology. J Infect Dis 180:1177–1185
17. Pe´rez-Herna´ndez X, Me´ndez-A´lvarez S, Claverie-Martı´n F
(2002) A rapid PCR assay for rapid detection of vancomycin-
resistant enterococci. Diagn Microbiol Infect Dis 42:273–277
18. Pe´rez-Roth E, Claverie-Martı´n F, Batista N, Moreno A,
Me´ndez-Alvarez S (2002) Mupirocin resistance in methicillin
resistant Staphylococcus aureus clinical isolates in a Spanish
hospital. Co-application of multiplex PCR assay and conven-
119
tional microbiology methods. Diagn Microbiol Infect Dis 43
(in press)
19. Pe´richon B, Reynolds P, Courvalin P (1997) VanD-type gly-
copeptide-resistant Enterococcus faecium BM4339. Antimicrob
Agents Chemother 41:2016–2018
20. Peset V, Tallon P, Sola C, Sanchez E, Sarrion A, Perez-Belles
C, Vindel A, Canton E, Gobernado M (2000) Epidemiological,
microbiological, clinical and prognostic factors of bacteremia
caused by high-level vancomycin-resistant Enterococcus
species. Eur J Clin Microbiol Infect Dis 19:742–749
21. Rice LB (2001) Emergence of vancomycin-resistant entero-
cocci. Emerg Infect Dis 7:183–187
22. Schouten MA, Hoogkamp-Korstanje JAA, Meis JFG, Voss A,
The European VRE Study Group (2000) Prevalence of
vancomycin-resistant enterococci in Europe. Eur J Clin
Microbiol Infect Dis 19:816–822
23. Woodford N (1998) Glycopeptide-resistant enterococci: a
decade of experience. J Med Microbiol 47:849–862
120
